about
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or BThe Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and BLow-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in ChinaAn Expanded Access Program of Emicizumab in Participants With Hemophilia A With InhibitorsRecombinant Factor VIIa (NovoSeven) on Restoring Coagulation ActivationSocialization of Adult Men With Congenital Hemophilia A or BThrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With InhibitorsStudy to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia ALong-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia AExpanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodiesStudy Evaluating On-Demand Treatment Of Xyntha In Chinese SubjectsInternational PMS Study - KOGENATE BayerA Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionWeb Accessible Population Pharmacokinetics Service - Hemophilia: Sources of VariabilityPharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding StatePrediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of ThromboelastographySafety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major SurgeryInhibitor Development in Patients With Hemophilia A Undergoing SurgeryEfficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia ASafety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia AStudy of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody DevelopmentA Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia ABAY81-8973 Pediatric Safety and Efficacy TrialA Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and InhibitorsA Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia AMultiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without InhibitorsMOTHIF II : THERAPEUTIC MANAGEMENT AND USE OF CLOTTING FACTORS IN HEMOPHILIA A & B IN FRANCE IIGene Therapy Study in Severe Haemophilia A Patients With Antibodies Against AAV5Long-Term Safety and Efficacy of SPK-8011 in Males With Hemophilia AStudy of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and BA Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without InhibitorsA Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With InhibitorsSingle-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kgEvaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement TherapiesEfficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A ParticipantsA Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) InhibitorsHemophilia Inhibitor Clinical Trials (INHIBIT) PlatformAn Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia AAssessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry: A Nested Study Within an Existing Registry
P4844
Q61707393-D9BFDC00-B0F1-48BD-BB6C-C03A0CE1D1DCQ61902404-65C5221D-B44D-48BD-B61D-DC44AF1E601BQ61907867-62D1C0C5-1BB9-4192-BEDA-5D6AF219C27AQ61909650-A7855B2C-A7C7-4D57-99CF-F5623A5767CAQ61932354-00FA119A-4615-4866-9AE7-69BD72DA8F79Q61956198-73AC75C0-DB2B-45A1-9F0D-30FB77D12BD6Q61957026-FB7C3D38-3616-47EF-8BBD-3CB584970977Q61965908-1F5C5B6C-74DE-4D04-AEDC-767EE802C7D5Q61966362-1856284A-DF07-495D-8279-501CC8C51D4CQ61975497-0D785C65-E886-4DE6-A874-FF962222B1F8Q61980802-9982222F-067D-4239-A420-7076196BE7B4Q61981151-CD8D706A-9159-411A-83C4-B6A9C5A6E9BDQ62034307-F04AA796-CCA5-448B-B517-32E67DBD2929Q62815287-0F4A4D7C-5B7F-4BC1-9472-1812230BFB9BQ63316140-35998AB5-3E8A-473B-A6DD-357999195A49Q63316287-8D8AE55A-7E23-49F1-BDBE-2BC5FFC0E3C6Q63316415-065E091A-FC09-4332-870A-A1A8A1A26721Q63316449-FE942B6B-4629-4BD4-BF32-ED5F67764EBEQ63317592-F021254D-23B2-46CE-9853-9706EE98E52EQ63319853-80E4D6C0-83A5-4D16-805B-EA71DFA9781EQ63321702-63F59BEB-1807-437C-B0BC-01CD62CFCF11Q63333822-337FC1F7-D308-4F2C-8C8C-CEFE24BE481CQ63339121-CA4F91FB-3DC9-42CA-BAFE-3758DFFC2060Q63340483-928B397E-1016-4B3D-9EF3-8B55A0603FE1Q63340824-9353E1A0-CADC-4F3E-A90E-7222214ADC73Q63340933-3A940AAE-97E1-40DA-B575-5081656C8467Q63394434-F184C9DC-1460-4B92-BD5D-EDBD391AA5C0Q63394471-643A29EC-DCEF-488C-8675-650B853C3580Q63397484-75C69D42-32CF-4A25-8A54-B267D395DDD5Q63403667-4CEF3618-0ACB-4CB2-9745-E71AACF23A71Q63403848-C7E12EF2-B047-4B2A-B8A2-435203B0CA17Q63404492-59D2F8B8-8142-4749-B64B-6F99709ECC29Q63404540-F30EB745-3F1B-494C-8C5D-BE5F7F2F236FQ63404579-C4B8E7E6-3764-40E1-93DD-10A29ADE8543Q63404746-BDE9CB86-2316-4888-B96B-F0A23282935EQ63570774-65087E1B-4C46-47FB-BF18-75C5C3D309D5Q63571170-8EE0F841-A37F-441E-8C3F-D96B8A4C929DQ63571457-94CB50E5-EB2E-4798-B643-684F5503DA0EQ63571464-CD2A2FE2-3C49-4ABD-8A3F-784EE5882C0FQ63571625-CC032986-CC24-4B46-8453-A970F447A70C
P4844
description
chemická sloučenina
@cs
chemische Verbindung
@de
chemische verbinding
@nl
component quimic
@oc
compost químic
@ca
composto chimico
@it
composto químico
@gl
composto químico
@pt
composto químico
@pt-br
composé chimique
@fr
name
Antihemophilic Factor
@en
facteur VIII
@fr
type
label
Antihemophilic Factor
@en
facteur VIII
@fr
altLabel
AHF
@en
Alphanate
@en
Bioclate
@en
Factor VIII
@en
Helixate
@en
Hemofil M
@en
Humafac
@en
Humate-P
@en
KOGENATE
@en
Koate-HP
@en
prefLabel
Antihemophilic Factor
@en
facteur VIII
@fr
P2175
P31
P592
P2115
N0000006037
N0000147710
P592
CHEMBL2108175